Downregulation of cannabinoid receptor 1 from neuropeptide Y interneurons in the basal ganglia of patients with Huntington's disease and mouse models
暂无分享,去创建一个
K. Mackie | Eric A. Horne | G. Bates | P. Muchowski | Xiaocui Sun | E. Grouzmann | N. Stella | Yi Hsing Lin | Susan Fung | Alipi V Naydenov | A. Cherry | J. Coy | C. Dirk Keene | Katie Swinney | William R. Marrs | Allison E. Cherry
[1] Masahiko Watanabe,et al. Unbalance of CB1 receptors expressed in GABAergic and glutamatergic neurons in a transgenic mouse model of Huntington's disease , 2012, Neurobiology of Disease.
[2] J. Tepper,et al. A Novel Functionally Distinct Subtype of Striatal Neuropeptide Y Interneuron , 2011, The Journal of Neuroscience.
[3] B. Shaby,et al. Identifying polyglutamine protein species in situ that best predict neurodegeneration , 2011, Nature chemical biology.
[4] E. Abercrombie,et al. In vivo Dopamine Efflux is Decreased in Striatum of both Fragment (R6/2) and Full-Length (YAC128) Transgenic Mouse Models of Huntington's Disease , 2011, Front. Syst. Neurosci..
[5] J. Tepper,et al. Heterogeneity and Diversity of Striatal GABAergic Interneurons , 2010, Front. Neuroanat..
[6] I. Bezprozvanny,et al. Corticostriatal circuit dysfunction in Huntington's disease: intersection of glutamate, dopamine and calcium. , 2010, Future neurology.
[7] Koen Van Laere,et al. Widespread Decrease of Type 1 Cannabinoid Receptor Availability in Huntington Disease In Vivo , 2010, The Journal of Nuclear Medicine.
[8] B. Hudson,et al. Physical and functional interaction between CB1 cannabinoid receptors and β2‐adrenoceptors , 2010, British journal of pharmacology.
[9] Carlos Cepeda,et al. Alterations in striatal synaptic transmission are consistent across genetic mouse models of Huntington's disease , 2010, ASN neuro.
[10] Anatol C. Kreitzer,et al. Distinct Roles of GABAergic Interneurons in the Regulation of Striatal Output Pathways , 2010, The Journal of Neuroscience.
[11] L. Raymond,et al. Early Increase in Extrasynaptic NMDA Receptor Signaling and Expression Contributes to Phenotype Onset in Huntington's Disease Mice , 2010, Neuron.
[12] L. Raymond,et al. Early Increase in Extrasynaptic NMDA Receptor Signaling and Expression Contributes to Phenotype Onset in Huntington's Disease Mice , 2010, Neuron.
[13] Michael R. Hayden,et al. Balance between synaptic versus extrasynaptic NMDA receptor activity influences inclusions and neurotoxicity of mutant huntingtin , 2009, Nature Medicine.
[14] A. Hannan,et al. Altered CB1 receptor and endocannabinoid levels precede motor symptom onset in a transgenic mouse model of Huntington's disease , 2009, Neuroscience.
[15] Anatol C. Kreitzer,et al. Physiology and pharmacology of striatal neurons. , 2009, Annual review of neuroscience.
[16] M. Isokawa. Time-dependent induction of CREB phosphorylation in the hippocampus by the endogenous cannabinoid , 2009, Neuroscience Letters.
[17] Y. Ben-Ari,et al. Dopamine-Deprived Striatal GABAergic Interneurons Burst and Generate Repetitive Gigantic IPSCs in Medium Spiny Neurons , 2009, The Journal of Neuroscience.
[18] J. Fernández-Ruiz. The endocannabinoid system as a target for the treatment of motor dysfunction , 2009, British journal of pharmacology.
[19] J. Tsien,et al. In Vivo Evidence for NMDA Receptor-Mediated Excitotoxicity in a Murine Genetic Model of Huntington Disease , 2009, The Journal of Neuroscience.
[20] L. Goldstein,et al. Enhanced Sensitivity of Striatal Neurons to Axonal Transport Defects Induced by Mutant Huntingtin , 2008, The Journal of Neuroscience.
[21] A. Parent,et al. The fate of the large striatal interneurons expressing calretinin in Huntington’s disease , 2008, Neuroscience Research.
[22] Carlos Cepeda,et al. Full-Length Human Mutant Huntingtin with a Stable Polyglutamine Repeat Can Elicit Progressive and Selective Neuropathogenesis in BACHD Mice , 2008, The Journal of Neuroscience.
[23] Michela Matteoli,et al. Hardwiring the Brain: Endocannabinoids Shape Neuronal Connectivity , 2007, Science.
[24] Michelle K. Lupton,et al. The Hdh Q150/Q150 knock-in mouse model of HD and the R6/2 exon 1 model develop comparable and widespread molecular phenotypes , 2007, Brain Research Bulletin.
[25] Masahiko Watanabe,et al. Subcellular Arrangement of Molecules for 2-Arachidonoyl-Glycerol-Mediated Retrograde Signaling and Its Physiological Contribution to Synaptic Modulation in the Striatum , 2007, The Journal of Neuroscience.
[26] T. Freund,et al. Subcellular localization of type 1 cannabinoid receptors in the rat basal ganglia , 2006, Neuroscience.
[27] L. Mucke,et al. A network dysfunction perspective on neurodegenerative diseases , 2006, Nature.
[28] Masahiko Watanabe,et al. Depolarization‐induced suppression of inhibition mediated by endocannabinoids at synapses from fast‐spiking interneurons to medium spiny neurons in the striatum , 2006, The European journal of neuroscience.
[29] E. S. Graham,et al. Induction of Krox-24 by Endogenous Cannabinoid Type 1 Receptors in Neuro2A Cells Is Mediated by the MEK-ERK MAPK Pathway and Is Suppressed by the Phosphatidylinositol 3-Kinase Pathway* , 2006, Journal of Biological Chemistry.
[30] R. Wightman,et al. Dopamine release is severely compromised in the R6/2 mouse model of Huntington's disease , 2006, Journal of neurochemistry.
[31] Carlos Cepeda,et al. Altered cortical glutamate receptor function in the R6/2 model of Huntington's disease. , 2006, Journal of neurophysiology.
[32] Anatol C. Kreitzer,et al. Dopamine Modulation of State-Dependent Endocannabinoid Release and Long-Term Depression in the Striatum , 2005, The Journal of Neuroscience.
[33] E Sylvester Vizi,et al. Involvement of Cannabinoid Receptors in the Regulation of Neurotransmitter Release in the Rodent Striatum: A Combined Immunochemical and Pharmacological Analysis , 2005, The Journal of Neuroscience.
[34] Carlos Cepeda,et al. Increased GABAergic function in mouse models of Huntington's disease: Reversal by BDNF , 2004, Journal of neuroscience research.
[35] Haibei Hu,et al. Structure, expression and regulation of the cannabinoid receptor gene (CB1) in Huntington's disease transgenic mice. , 2004, European journal of biochemistry.
[36] Mark R. Segal,et al. Inclusion body formation reduces levels of mutant huntingtin and the risk of neuronal death , 2004, Nature.
[37] G. Bernardi,et al. Immunolocalization of CB1 receptor in rat striatal neurons: A confocal microscopy study , 2004, Synapse.
[38] J. Littleton,et al. Cytoplasmic aggregates trap polyglutamine-containing proteins and block axonal transport in a Drosophila model of Huntington's disease. , 2004, Proceedings of the National Academy of Sciences of the United States of America.
[39] Wilhelm Gaus,et al. Evidence for more widespread cerebral pathology in early HD: An MRI-based morphometric analysis , 2004, Neurology.
[40] M. Eder,et al. CB1 Cannabinoid Receptors and On-Demand Defense Against Excitotoxicity , 2003, Science.
[41] Richard G. Brusch,et al. Disruption of Axonal Transport by Loss of Huntingtin or Expression of Pathogenic PolyQ Proteins in Drosophila , 2003, Neuron.
[42] J. Girault,et al. Regulation of Extracellular Signal-Regulated Kinase by Cannabinoids in Hippocampus , 2003, The Journal of Neuroscience.
[43] Carlos Cepeda,et al. Transient and Progressive Electrophysiological Alterations in the Corticostriatal Pathway in a Mouse Model of Huntington's Disease , 2003, The Journal of Neuroscience.
[44] W. Zieglgänsberger,et al. The endogenous cannabinoid system controls extinction of aversive memories , 2002, Nature.
[45] H. Bading,et al. Extrasynaptic NMDARs oppose synaptic NMDARs by triggering CREB shut-off and cell death pathways , 2002, Nature Neuroscience.
[46] N. Stella,et al. Receptor-dependent formation of endogenous cannabinoids in cortical neurons. , 2001, European journal of pharmacology.
[47] R. Albin,et al. Neurological abnormalities in a knock-in mouse model of Huntington's disease. , 2001, Human molecular genetics.
[48] H. Robertson,et al. Cannabinoid receptor messenger RNA levels decrease in a subset of neurons of the lateral striatum, cortex and hippocampus of transgenic Huntington’s disease mice , 2000, Neuroscience.
[49] M. Herkenham,et al. Localization of cannabinoid CB1 receptor mRNA in neuronal subpopulations of rat striatum: A double‐label in situ hybridization study , 2000 .
[50] C A Ross,et al. Decreased expression of striatal signaling genes in a mouse model of Huntington's disease. , 2000, Human molecular genetics.
[51] M. Dragunow,et al. The pattern of neurodegeneration in Huntington's disease: a comparative study of cannabinoid, dopamine, adenosine and GABAA receptor alterations in the human basal ganglia in Huntington's disease , 2000, Neuroscience.
[52] S. Finkbeiner. CREB Couples Neurotrophin Signals to Survival Messages , 2000, Neuron.
[53] G P Bates,et al. Ultrastructural localization and progressive formation of neuropil aggregates in Huntington's disease transgenic mice. , 1999, Human molecular genetics.
[54] L. Parsons,et al. Dopamine activation of endogenous cannabinoid signaling in dorsal striatum , 1999, Nature Neuroscience.
[55] S. W. Davies,et al. Aggregation of huntingtin in neuronal intranuclear inclusions and dystrophic neurites in brain. , 1997, Science.
[56] S. W. Davies,et al. Exon 1 of the HD Gene with an Expanded CAG Repeat Is Sufficient to Cause a Progressive Neurological Phenotype in Transgenic Mice , 1996, Cell.
[57] P. Casellas,et al. Activation of mitogen-activated protein kinases by stimulation of the central cannabinoid receptor CB1. , 1995, The Biochemical journal.
[58] M. Herkenham,et al. Selective vulnerability in Huntington's disease: Preferential loss of cannabinoid receptors in lateral globus pallidus , 1994, Annals of neurology.
[59] R. Faull,et al. Loss of cannabinoid receptors in the substantia nigra in huntington's disease , 1993, Neuroscience.
[60] Manish S. Shah,et al. A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes , 1993, Cell.
[61] M. Burnier,et al. Production and characterization of four anti-neuropeptide Y monoclonal antibodies. , 1992, Hybridoma.
[62] M. Herkenham,et al. Characterization and localization of cannabinoid receptors in rat brain: a quantitative in vitro autoradiographic study , 1991, The Journal of neuroscience : the official journal of the Society for Neuroscience.
[63] R. Ferrante,et al. Neuropathological Classification of Huntington's Disease , 1985, Journal of neuropathology and experimental neurology.
[64] P. Emson,et al. Survival of basal ganglia neuropeptide Y-somatostatin neurones in Huntington's disease , 1985, Brain Research.
[65] Joseph B. Martin. Huntington's disease , 1984, Neurology.
[66] J. Lucas,et al. Loss of striatal type 1 cannabinoid receptors is a key pathogenic factor in Huntington's disease. , 2011, Brain : a journal of neurology.
[67] T. Rubino,et al. Changes in the expression of G protein-coupled receptor kinases and beta-arrestins in mouse brain during cannabinoid tolerance: a role for RAS-ERK cascade. , 2006, Molecular neurobiology.
[68] Wolfgang Schmid,et al. Disruption of CREB function in brain leads to neurodegeneration , 2002, Nature Genetics.
[69] D. Lovinger,et al. CB1 cannabinoid receptor inhibits synaptic release of glutamate in rat dorsolateral striatum. , 2001, Journal of neurophysiology.
[70] M. Herkenham,et al. Localization of cannabinoid CB(1) receptor mRNA in neuronal subpopulations of rat striatum: a double-label in situ hybridization study. , 2000, Synapse.
[71] Alcino J. Silva,et al. CREB and memory. , 1998, Annual review of neuroscience.